Asthma and COPD are two of the fastest growing disease states. There are 17 million Americans with asthma and 15 million with COPD (by 2010 there will be 30 million with COPD. COPD is often undiagnosed in its early stages, especially in smokers, who are most at risk and as a result not receiving treatment.
Since early detection and treatment of COPD can positively influence the disease course, it is important to screen those patients at risk. The Microlife is the ideal tool to use as a quick check of lung function to highlight signs of disease as early as possible.
The Microlife revolutionary peak flow meter with FEV1 is the doctor’s choice for managing diseases that restrict lung performance. This advanced meter for spirometry includes a digital diary and measures air flow velocity and volume (FEV1) to indicate early warning signs for impending asthmatic incidents or conditions. Using these measurements in conjunction with a doctor’s consultation allows patients with asthma, COPD and other lung diseases to manage their condition.
The optional PC software works with the Microlife to easily chart and graph progress that can be printed and shared with a physician.